Renal replacement therapy for diabetic patients

  • Yalem Woredekal
  • Eli A. Friedman


Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in the United States, Japan, and most of industrialized Europe. Patients with diabetes currently account for 40.3% of all patients enrolled in the Medicare ESRD program (1), and the number of new diabetic patients accepted for renal replacement therapy has been increasing steadily for the past decade from 32.9% in 1989 to 44.4% in 1997 (Figure 1). Although the relative rates of ESRD treatment in Europe and Canada are about half that in the United States, a similar progressive increase in the proportion of incident patients with diabetes is reported (2).


Diabetic Patient Diabetic Nephropathy Peritoneal Dialysis Renal Replacement Therapy Hemodialysis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    United States Renal Data System (USRDS). 2000 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000.Google Scholar
  2. 2.
    Maisonneuve P, Agodoa L, Gellert R et al. Distribution of primary renal disease leading to end stage renal failure in Unites States, Europe, Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000; 35:157–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Chazan BI, Rees SB, Balodimus MS et al. Dialysis in diabetics: a review of 44 patients. J Am Med Assoc. 1969;209: 2026–30.CrossRefGoogle Scholar
  4. 4.
    Comty CM, Kjellsen D, Shapiro FL. A reassessment of the prognosis of diabetic patients treated by chronic hemodialysis. Trans Am Soc Artif Intern Organs. 1976;22:404–11.PubMedGoogle Scholar
  5. 5.
    Ghavamian M, Gutch CF, Kopp KF et al. The sad truth about hemodialysis in diabetic nephropathy. J Am Med Assoc. 1972;222:1386–9.CrossRefGoogle Scholar
  6. 6.
    Jacobs C, Broyer M, Brunner FP et al. Combined report on regular dialysis and transplantation Association in Europe, XI, 1980. Presented at the 17th Congress of the European Dialysis and Transplantation Association, Paris, 5–8 July 1981.Google Scholar
  7. 7.
    Yokoyama H, Okudaira M, Otani T et al. Higher incidence of diabetic nephropathy in type 2 than type 1 diabetes in early onset diabetes in Japan. Kidney Int. 2000;58:302–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Hamphrey LL, Ballard DI, Frohnert PP et al. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med. 1989;111:788–96.CrossRefGoogle Scholar
  9. 9.
    Cowie CC, Port FK, Wolfe RA et al. Disparities in incidence of diabetic end-stage renal disease. N Engl J Med. 1989; 321:1074–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Stephens GW, Gillaspy JA, Clyne D, Mejea A, Pollak VE. The racial differences in the incidence of end stage renal disease in type I & II diabetes mellitus. Am J Kidney Dis. 1990;15:562–7.PubMedGoogle Scholar
  11. 11.
    Pugh JA, Medin RA, Cornell JC, Basu S. NIDDM is the major cause of diabetic end stage renal disease. More evidence from a tri-ethnic community. Diabetes. 1995;44:375–80.CrossRefGoogle Scholar
  12. 12.
    Nelson RG, Newman JM, Knowles WC et al. Incidence of end-stage renal disease in type 2 (non-insulin dependent) diabetes mellitus in Pima Indians. Diabetologia. 1988;31: 730–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Munita B, Newman J, Stevenson J, Egger P. Diabetic end stage renal disease among Native Americans. Diabetes Care. 1993;16:346–8.CrossRefGoogle Scholar
  14. 14.
    Chantrel F, Bouiller M, Kolb L, Hannedouche T. Antihypertensive treatment in type 2 diabetes and diabetic nephropathy. Nephrologie. 2000;21:47–52.PubMedGoogle Scholar
  15. 15.
    Ruggenenti P, Pema A, Gherdi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 362 patients with different patterns of renal injury. Am J Kidney Dis. 2000;35:1155–65.PubMedCrossRefGoogle Scholar
  16. 16.
    Chan JC, Ko GT, Leung DH et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 2000;57:590–600.PubMedCrossRefGoogle Scholar
  17. 17.
    Diabetic Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complication. N Engl J Med. 1993:329:304–9.CrossRefGoogle Scholar
  18. 18.
    United Kingdom Prospective Diabetes Study Group. Intensive glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes mellitus. Ann Intern Med. 1997;127:788–95.CrossRefGoogle Scholar
  19. 19.
    Pijls LT, DeUries H, Donker AJ, Van Eijk JT. The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant. 1999;14:1445–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Hansen HP, Christensen PK, Tauber-Lassen E et al. Low protein diet and kidney function in insulin dependent diabetic patients with nephropathy. Kidney Int. 1999;55:621–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ. Long-term effects of protein restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care. 1993;16:483–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Raal FJ, Kalk WJ, Lawson M et al. Effects of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-month prospective study. Am J Clin Nutr. 1994;60:579–85.PubMedGoogle Scholar
  23. 23.
    Cohen LM, Germain M, Poppel DM, Woods A, Kjellstrand CM. Dialysis discontinuation and palliative care. Am J Kidney Dis. 2000; 36:140–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Berman DH, Friedman EA, Lundin AP. Aggressive ophthalmological management in diabetic ESRD: a study of 31 consecutively referred patients. Am J Nephrol. 1992;12:344–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Watanabe Y, Yuzawa Y, Mizumoto D et al. Long-term follow-up study of 268 diabetic patients undergoing hemodialysis, with special attention to visual acuity and heterogeneity. Nephrol. Dial Transplant. 1993;8:725–34.PubMedGoogle Scholar
  26. 26.
    Legrain M, Rottenburg J, Bentchikou A et al. Dialysis treatment of insulin-dependent diabetic patients. Ten years experience. Clin Nephrol. 1984; 21: 72–81.PubMedGoogle Scholar
  27. 27.
    Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction, and cardiovascular risk. Diabetes Metab. 2000; 26(4): 464–6.Google Scholar
  28. 28.
    Nosadini R, Brocco E. Relationship among microalbuminuria, insulin resistance, and renal-cardiac complication in insulin dependent and non-insulin dependent diabetes. Exp Clin Endocrinol Diabetes. 1997;105:1–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Valmdrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older onset diabetes mellitus. Arch Intern Med. 2000;160:1093–100.CrossRefGoogle Scholar
  30. 30.
    Chantreal F, Enache I, Bouiller M et al. Abysmal prognosis of patients with type2 diabetes entering dialysis. Nephrol Dial Transplant. 1999; 14:129–36.CrossRefGoogle Scholar
  31. 31.
    Friedman EA. Physician bias in uremic therapy. Kidney Int. 1985;(Suppl. A):S38–40.Google Scholar
  32. 32.
    Ritz E, Strumpf C, Katz F, Wing AJ, Quellhorst E. Hypertension and cardiovascular risk factors in hemodialyzed diabetic patients. Hypertension. 1985;7:I1–118-24.CrossRefGoogle Scholar
  33. 33.
    Cheigh J, Raghavan J, Sullivan J et al. Is insufficient dialysis a cause for high morbidity in diabetic patients? J Am Soc Nephrol. 1990;317(abstract).Google Scholar
  34. 34.
    Scideman JR, Buselmeir TJ, Kjellstrand CM. Hemodialysis in diabetics. Arch Intern Med. 1976;136:1126–30.CrossRefGoogle Scholar
  35. 35.
    Mann NK, Fournier G, Thireau P, Gaillard JL, Funck-Brentano JL. Artif Organs. 1982; 6:421–8.CrossRefGoogle Scholar
  36. 36.
    Keshaviah PR. The role of acetate in the etiology of symptomatic hypotension. Artif Organs. 1982;6:378–87.PubMedCrossRefGoogle Scholar
  37. 37.
    Gotch FA, Keen ML, Yarian SR. An analysis of counter regulation in hemodialysis with one and three compartment models. Trans Am Soc Artif Intern Organs. 1989;35:622–4.CrossRefGoogle Scholar
  38. 38.
    Quereda C, Mercen R, Lamas S. et al. Hemodialysisassociated hypotension and dialysate temperature. Life Support Syst. 1985;3:18–22.PubMedGoogle Scholar
  39. 39.
    Maggiore Q, Pizarelli F, Zocalli C et al. Effects of extracorporeal blood cooling on dialytic arterial hypotension. Proc Eur Dial Transplant Assoc. 1981;28:686–9.Google Scholar
  40. 40.
    Hampl H, Berweck S, Ludat K, Fischer HC, Hertel J. How can hemodialysis-associated hypotension and dialysisinduced symptoms be explained and controlled, particularly in diabetic atherosclerotic patients? Clin Nephrol. 2000; 53(Suppl. 1):S69–79.Google Scholar
  41. 41.
    Strayer B, de Vries PM, ten Voorde BJ et al. Intradialytic hypotension in relation to preexistent autonomic dysfunction in hemodialysis patients. Int J Artif Organs. 1998;21:794–801.Google Scholar
  42. 42.
    Peosi G, Emdin M, Carpeggiani C et al. Impaired sympathetic response before intradialytic hypotension: a study based on spectral analysis of heart rate and pressure variability. Clin Sci. 1999;96:23–31.CrossRefGoogle Scholar
  43. 43.
    Dougirdas JT. Dialysis hypotension. A hemodynamic analysis. Kidney Int. 1991;39:223.Google Scholar
  44. 44.
    Cice G, Tagliamonte E, Ferara L et al. Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotension crisis. Cardiologia. 1999; 44:289–94.PubMedGoogle Scholar
  45. 45.
    Anand V, Bastani B, Dhanraj P, Ballal SH. Intradialytic dobutamine therapy in maintenance hemodialysis patients with hypotension. Am J Nephrol. 1999;19:459–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Am J Kidney Dis. 1999;33:920–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Ifudu O, Dulin AL, Friedman EA. Interdialytic weight gain correlates with glycosylated hemoglobin in diabetic hemodialysis patients. Am J Kidney Dis. 1994;23:686–91.PubMedGoogle Scholar
  48. 48.
    Kimmel PL, Varela MP, Peterson RA et al. Interdialytic weight gain and survival in hemodialysis patients, effects of duration of ESRD and diabetic mellitus. Kidney Int. 2000; 57:1141–51.PubMedCrossRefGoogle Scholar
  49. 49.
    Rahman M, Fu P, Sehgal AR, Smith MC. Interdialytic weight gain, compliance with dialytic regime and age are independent predictors of blood pressure in hemodialysis patients. Am J Kidney Dis. 2000; 35:257–65.PubMedCrossRefGoogle Scholar
  50. 50.
    Koch M, Tschope W, Ritz E. Does the care of diabetic patients with renal failure in the predialysis phase need improvement? Dtsch Med Wochenschr. 1991;116:1543–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Kirkman RL. Techniques for flow reduction in dialysis access fistula. Surg Gynecal Obstet. 1991;172:231–3.Google Scholar
  52. 52.
    Newman GE, Davidson CI, Mc Cann RL, Schwab SJ. Functional restenosis rate after hemodialysis graft angioplasty. J Am Soc Nephrol. 1991;2:341.Google Scholar
  53. 53.
    Swedberg SH, Brown BG, Sigley R et al. Intimal fibromascular hyperplasia in the venous anastomosis of PTFE graft in hemodialysis patients. Clinical immunocytochemical, light and electron microscopic assessment. Circulation. 1989;81:1726–36.CrossRefGoogle Scholar
  54. 54.
    Collins DM, Lambert MB, Middleton JP et al. Fistula dysfunction effect on rapid hemodialysis. Kidney Int. 1992;41: 1292–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Windus DW, Audrain J, Vanderson R et al. Optimization of high efficiency hemodialysis by detection and correction of fistula dysfunction. Kidney Int. 1990;38:337–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Beathaid GA. Percutaneous transvenous angioplasties in the treatment of vascular access stenosis. Kidney Int. 1992;42: 1390–7.CrossRefGoogle Scholar
  57. 57.
    Palder SB, Kirkman RL, Whittemore AD. Vascular access for hemodialysis: patency rates and results of revision. Am Surg. 1985;202:235–9.Google Scholar
  58. 58.
    Bhat DJ, Tellis VA, Koldberg WJ, Driscoll B, Veith Management of sepsis involving expanded polytetrafluoroethylene graft for hemodialysis access. Surgery. 1980; 87:945–50.Google Scholar
  59. 59.
    Horowitz DK, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia. 1994;37:543–51.PubMedCrossRefGoogle Scholar
  60. 60.
    Annese V, Vassotti G, Caruso N et al. Gastrointestinal motor dysfunction, symptoms, and neuropathy in non-insulin-dependent diabetes mellitus. J Clin Gastroenterol. 1999;29:171–7PubMedCrossRefGoogle Scholar
  61. 61.
    Eisenberg B, Murata GH, Tzamaloukas AH, Zager PG, Avasthi PS. Gastroparesis in diabetics on chronic dialysis: clinical and laboratory associations and predictive features. Nephron. 1994;70:296–300CrossRefGoogle Scholar
  62. 62.
    Drenth JP, Engels LF. Gastroparesis. A critical reappraisal of new treatment strategies. Drugs. 1992;44:537–53PubMedCrossRefGoogle Scholar
  63. 63.
    Campese VM, Procci WR, Levitan D et al. Autonomic nervous system dysfunction and impotence in uremia. Am J Nephrol. 1982;2:140–3.PubMedCrossRefGoogle Scholar
  64. 64.
    Kinugasa E, Tayama H, Sato Y. Sexual dysfunction in the male patients on hemodialysis. Nippon Rinsho. 1997;55: 2996–3001PubMedGoogle Scholar
  65. 65.
    Malavaud B, Rostaing L, Rischmann P, Sarramon JP, Dwand D. High prevalence of erectile dysfunction after renal transplantation. Transplantation. 2000;69:2121–4PubMedCrossRefGoogle Scholar
  66. 66.
    Breza J, Rezmiak J, Pribylincova B, Zvara P. Erectile dysfunction in patients treated with hemodialysis and kidney transplant. Bratisl Lek Listy. 1993;4:489–93Google Scholar
  67. 67.
    Spollett GR. Assessment and management of erectile dysfunction in men with diabetes. Diabetes EDU. 1999;25:65–73CrossRefGoogle Scholar
  68. 68.
    Tsai YS, Lin JS, Lin YM. Safety and efficacy of alprostadil Sterile powder (S. Po.. CAVERJECT) in diabetic patients with erectile dysfunction. Eur Urol. 2000;38:177–83PubMedCrossRefGoogle Scholar
  69. 69.
    Vincenti F, Hattner R, Amend WJ Jr et al. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. J Am Med Assoc. 1981;6:930–3CrossRefGoogle Scholar
  70. 70.
    Pei Y, Herez G, Greenwood C et al. Risk factors for renal osteodystrophy: multivariate analysis. J Bone Miner Res. 1995;10:149–56PubMedCrossRefGoogle Scholar
  71. 71.
    Hernandez D, Concepcion MT, Lorenzo V et al. Adynamic bone disease with negative aluminum staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant. 1994;9:317–23Google Scholar
  72. 72.
    Holgado R, Haire H, Ross D et al. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000;15:927–35PubMedCrossRefGoogle Scholar
  73. 73.
    Hamburger RJ, Christ PG, Morris PA, Luft FC. Hypertension in dialysis patients: does CAPD provide an advantage? Adv Pert Dial. 1989;5:91–6Google Scholar
  74. 74.
    Lindblad AS, Nolph KD, Novak JS, Friedman EA. A survey of the NIH CAPD Registry population with end-stage renal disease attributed to diabetic nephropathy. J Diabet Complic. 1988;2:227–32CrossRefGoogle Scholar
  75. 75.
    Scarpioni LL, Ballocchi S, Castelli A, Cecchetin M, Poisetti PG. Continuous ambulatory peritoneal dialysis in diabetic patients. Contrib Nephrol. 1990;84:60–74PubMedGoogle Scholar
  76. 76.
    Maiorca R, Vonesh E, Cancarini GC et al. A six year comparison of patients and technique survival in CAPD and HD. Kidney Int. 1988;34:518–24PubMedCrossRefGoogle Scholar
  77. 77.
    Blumenkrantz MJ, Gahl GM, Kopple JD et al. Protein losses during peritoneal dialysis. Kidney Int. 1981;19:593–602PubMedCrossRefGoogle Scholar
  78. 78.
    Krediet RT, Zuyderhoudt FMJ, Boeschoten EW, Arisz I. Diagnosis of protein-calorie malnutrition in diabetic patients on hemodialysis and peritoneal dialysis. Nephron. 1986;42:133–40PubMedCrossRefGoogle Scholar
  79. 79.
    Marso SP, Lincoff AM, Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation. 1999; 100:2477–84PubMedCrossRefGoogle Scholar
  80. 80.
    Mazzuchi N, Gonzalez-Martinez F, Carbonell E et al. Comparison of survival for hemodialysis patients vs renal transplant recipients treated in Uruguay. Nephrol Dial Transplant. 1999;14:2849–54PubMedCrossRefGoogle Scholar
  81. 81.
    Khauli RB, Steinmuller DR, Movick AC et al. A critical look at survival of diabetics with end-stage renal disease: transplantation versus dialysis. Transplantation. 1986;41: 598–602PubMedCrossRefGoogle Scholar
  82. 82.
    Cecka JM. UNOS Scientific Renal Transplant Registry. Clin Transplant. 1996;6:1–14Google Scholar
  83. 83.
    Cecka JM. UNOS Scientific Renal Transplant Registry. Clin Transplant. 1999:1–21Google Scholar
  84. 84.
    Becker BN, Brazy PC, Becker YT et al. Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int. 2000;57:2129–35.PubMedCrossRefGoogle Scholar
  85. 85.
    Secchi A, Marinenghi S, Castoldi R et al. Effects of pancreas transplantation on quality of life in type 1 diabetic patients undergoing kidney transplantation. Transplant Proc. 1998; 30:339–42PubMedCrossRefGoogle Scholar
  86. 86.
    Bitker MO, Barrou B, Mouquet C et al. Combined renal and pancreas transplantation as treatment for chronic renal insufficiency of diabetic origin: a series of 50 consecutive transplantation. Chirurgie. 1999;124:476–83PubMedCrossRefGoogle Scholar
  87. 87.
    Hricik DE, Chareandee C, Knauss TC, Schulak JA. Hypertension after pancreas-kidney transplantation: role of bladder versus enteric pancreatic drainage. Transplantation. 2000;70: 494–6PubMedCrossRefGoogle Scholar
  88. 88.
    Biesenbach G, Margreiter R, Kinigstrainer A et al. Comparisons of progression of macrovascular diseases after kidney-pancreas and kidney transplantation in diabetic patients with end-stage renal disease. Diabetologia. 2000;45:231–4CrossRefGoogle Scholar
  89. 89.
    Lo Rocca E, Gobbi C, Ciurlino D et al. Improvement of glucose/insulin metabolism reduces hypertension in insulindependent diabetes mellitus recipients of kidney-pancreas transplantation. Transplantation. 1999;65:390–3CrossRefGoogle Scholar
  90. 90.
    Cashion AK, Hathaway DK, Milstead EJ, Reed I, Gaber AO. Changes in patterns of 24 h heart rate variability after kidney and kidney-pancreas transplant. Transplantation. 1999;68: 1846–50PubMedCrossRefGoogle Scholar
  91. 91.
    Hathaway DK, Abell T, Cardoso S et al. Improvement in autonomic and gastric function following pancreas-kidney vs kidney alone transplantation and the correlation with quality of life. Transplantation. 1994;576:6–22Google Scholar
  92. 92.
    Kendall DM, Rooney DP, Smets YF et al. Pancreas transplantation restores epinephrine response and symptoms recognition during hypoglycemia in patients with longstanding type 1 diabetic and autonomic neuropathy. Diabetes. 1997;46: 249–57PubMedCrossRefGoogle Scholar
  93. 93.
    Chow VC, Pai RP, Chapman JR et al. Diabetic retinopathy after combined kidney-pancreas transplantation. Clin Transplant. 1999;13:356–62PubMedCrossRefGoogle Scholar
  94. 94.
    Pearce IA, Liango B, Sells RA, Wong D. Stabilization of diabetic retinopathy following simultaneous pancreas and kidney transplant. Br J Ophthalmol. 2000;84:736–40PubMedCrossRefGoogle Scholar
  95. 95.
    Tyden G, Bolinder J, Solder G et al. A 10 year prospective study of IDDM patients subjected to combined pancreas and kidney transplantation or kidney transplantation alone. Transplant Proc. 1998;30:332PubMedCrossRefGoogle Scholar
  96. 96.
    Sasaki TM, Gray RS, Ratner RE et al. Successful long-term kidney-pancreas transplants in diabetic patients with high C-peptide levels. Transplantation. 1998;65:1510–12PubMedCrossRefGoogle Scholar
  97. 97.
    Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR. Serum C-peptide concentration poorly phenotype type 2 diabetic end-stage renal disease patients. Kidney Int. 2000;58:1742–50PubMedCrossRefGoogle Scholar
  98. 98.
    Wang PH, Kore M. Searching for the Holy Grail: the cause of diabetes. Lancet. 1995;346:s4CrossRefGoogle Scholar
  99. 99.
    Porte D Jr, Schwartz MW. Diabetes complications: why is glucose potentially toxic? Science. 1996;272:699–70.PubMedCrossRefGoogle Scholar
  100. 100.
    Soulis-Liparota T, Cooper MF, Dunlop M et al. The relative role of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague Dawley rat. Diabetologia. 1995;38:387–94.PubMedCrossRefGoogle Scholar
  101. 101.
    Craven PA, Studer RK, Negrete H et al. Protein kinase C in diabetic nephropathy. J Diabetes Complic. 1995;9: 241–5.CrossRefGoogle Scholar
  102. 102.
    Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest. 1995;96:1395–403.PubMedCrossRefGoogle Scholar
  103. 103.
    Knowx LK, Stewart AG, Hayward PG et al. Nitric oxide synthase inhibitors improve skin flap survival in the rat. Microsurgery. 1994;15:708–11.CrossRefGoogle Scholar
  104. 104.
    Tilton RG, Chang K, Corbett JA et al. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci. 1994;35:3278–88.PubMedGoogle Scholar
  105. 105.
    Vlassara H, Fuh H, Makita Z et al. Exogenous advanced glycosylated end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complication. Proc Natl Acad Sci USA. 1992;89:12043–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Papanastasiou P, Grass I, Rodela H et al. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int. 1994;46:216–22.PubMedCrossRefGoogle Scholar
  107. 107.
    Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836–42.PubMedCrossRefGoogle Scholar
  108. 108.
    Ellis EN, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism. 1991;40:1016–19.PubMedCrossRefGoogle Scholar
  109. 109.
    Hammes HP, Martin S, Federlin K et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 1991;88: 11555–8PubMedCrossRefGoogle Scholar
  110. 110.
    Yagihashi S, Kamijo M, Baba M et al. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes. 1992;41:47–52PubMedCrossRefGoogle Scholar
  111. 111.
    Nakamura S, Makita Z, Ishikawa S et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes. 1997;46:895–9PubMedCrossRefGoogle Scholar
  112. 112.
    Lai MA, Körner A, Matsuo Y et al. A combined antioxidant and COMT inhibitor treatment reverse renal abnormalities in diabetic rat. Diabetes. 2000;49:1381–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2004

Authors and Affiliations

  • Yalem Woredekal
  • Eli A. Friedman

There are no affiliations available

Personalised recommendations